266 related articles for article (PubMed ID: 11544557)
1. Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer.
Flötotto T; Djahansouzi S; Gläser M; Hanstein B; Niederacher D; Brumm C; Beckmann MW
Horm Metab Res; 2001 Aug; 33(8):451-7. PubMed ID: 11544557
[TBL] [Abstract][Full Text] [Related]
2. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
3. The influence of hormones on CD44 expression in endometrial and breast carcinomas.
Durst B; Sorg RV; Röder G; Betz B; Beckmann MW; Niederacher D; Bender HG; Dall P
Oncol Rep; 2001; 8(5):987-93. PubMed ID: 11496303
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptors: selective ligands, partners, and distinctive pharmacology.
Katzenellenbogen BS; Montano MM; Ediger TR; Sun J; Ekena K; Lazennec G; Martini PG; McInerney EM; Delage-Mourroux R; Weis K; Katzenellenbogen JA
Recent Prog Horm Res; 2000; 55():163-93; discussion 194-5. PubMed ID: 11036937
[TBL] [Abstract][Full Text] [Related]
5. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer.
Lee AV; Cui X; Oesterreich S
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4429s-4435s; discussion 4411s-4412s. PubMed ID: 11916236
[TBL] [Abstract][Full Text] [Related]
6. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
[TBL] [Abstract][Full Text] [Related]
7. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
Newman SP; Bates NP; Vernimmen D; Parker MG; Hurst HC
Oncogene; 2000 Jan; 19(4):490-7. PubMed ID: 10698518
[TBL] [Abstract][Full Text] [Related]
8. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
[TBL] [Abstract][Full Text] [Related]
9. Steroid hormone receptor signaling in tumorigenesis.
Singh RR; Kumar R
J Cell Biochem; 2005 Oct; 96(3):490-505. PubMed ID: 16092128
[TBL] [Abstract][Full Text] [Related]
10. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
[TBL] [Abstract][Full Text] [Related]
11. Steroid receptors and their role in the biology and control of breast cancer growth.
Cordera F; Jordan VC
Semin Oncol; 2006 Dec; 33(6):631-41. PubMed ID: 17145341
[TBL] [Abstract][Full Text] [Related]
12. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries.
De Sousa Damião R; Fujiyama Oshima CT; Stávale JN; Gonçalves WJ
Oncol Rep; 2007 Jul; 18(1):25-32. PubMed ID: 17549341
[TBL] [Abstract][Full Text] [Related]
15. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.
Bagatell R; Khan O; Paine-Murrieta G; Taylor CW; Akinaga S; Whitesell L
Clin Cancer Res; 2001 Jul; 7(7):2076-84. PubMed ID: 11448926
[TBL] [Abstract][Full Text] [Related]
16. Anti-estrogens in the treatment of breast cancer: current status and future directions.
Barker S
Curr Opin Investig Drugs; 2003 Jun; 4(6):652-7. PubMed ID: 12901222
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
18. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
[TBL] [Abstract][Full Text] [Related]
19. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
20. Potential benefits of estrogens and progestogens on breast cancer.
Schneider HP; Jackisch C
Int J Fertil Womens Med; 1998; 43(6):278-85. PubMed ID: 9920536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
